Loading...

PE anti-mouse CD279 (PD-1) Antibody PE anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
RMP1-30 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed Death-1, CD279, PDCD1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RMP1-30
Con A (3-day) activated C57BL/6 mouse splenocytes stained with RMP1-30 PE
  • RMP1-30
    Con A (3-day) activated C57BL/6 mouse splenocytes stained with RMP1-30 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
109103 50 µg DKK725
Check Availability


Need larger quantities of this item?
Request Bulk Quote
109104 200 µg DKK2097
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279 is a 50-55 kD immunoglobulin superfamily member also known as programmed death-1 (PD-1). PD-1 is expressed on a subset of CD4-CD8- thymocytes and on activated T and B cells. PD-1 is thought to be involved in lymphocyte clonal selection and peripheral tolerance. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse PD-1 transfected BHK cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RMP1-30 antibody does not block the binding of PD-1 to B7-H1 and B7-DC1.

Application References
  1. Matsumoto K, et al. 2004. J. Immunol. 172:2530.
  2. Raimondi G, et al. 2006. J. Immunol. 176:2808. (FC) PubMed
  3. King IL, et al. 2009. J. Exp Med 206:1001. (FC) PubMed
Product Citations
  1. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  2. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  3. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  4. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  5. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  8. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  9. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  10. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  11. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  12. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  13. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  14. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  15. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  16. Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
  17. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  18. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  19. Bally A, et al. 2015. J Immunol. 194:4545. PubMed
  20. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  21. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  22. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  23. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  24. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  25. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  26. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  27. An J, et al. 2022. iScience. 25:103570. PubMed
  28. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  29. Zeng W, et al. 2016. Sci Rep. 6:36560. PubMed
  30. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  31. Karnowski A, et al. 2012. J Exp Med. 209:2049. PubMed
  32. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  33. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  34. Park S, et al. 2014. J Leukoc Biol. 95:621. PubMed
  35. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  36. Li H, et al. 2020. Nature. 584:274. PubMed
  37. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  38. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  39. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  40. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  41. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  42. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  43. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  44. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  45. Puleston D, et al. 2014. Elife. 3:3706. PubMed
  46. Park H, et al. 2012. Cell Immunol. 278:76. PubMed
  47. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  48. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  49. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  50. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  51. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  52. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  53. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  54. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  55. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  56. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  57. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  58. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  59. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  60. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  61. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  62. Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
  63. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  64. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  65. Bally A, et al. 2015. J Immunol. 194:4545. PubMed
  66. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  67. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  68. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  69. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  70. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  71. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  72. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  73. An J, et al. 2022. iScience. 25:103570. PubMed
  74. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  75. Zeng W, et al. 2016. Sci Rep. 6:36560. PubMed
  76. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  77. Karnowski A, et al. 2012. J Exp Med. 209:2049. PubMed
  78. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  79. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  80. Park S, et al. 2014. J Leukoc Biol. 95:621. PubMed
  81. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  82. Li H, et al. 2020. Nature. 584:274. PubMed
  83. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  84. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  85. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  86. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  87. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  88. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  89. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  90. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  91. Puleston D, et al. 2014. Elife. 3:3706. PubMed
  92. Park H, et al. 2012. Cell Immunol. 278:76. PubMed
RRID
AB_313420 (BioLegend Cat. No. 109103)
AB_313421 (BioLegend Cat. No. 109104)

Antigen Details

Structure
Ig superfamily, 50-55 kD
Distribution

Subset of double negative thymocytes, activated T and B cells

Function
Lymphocyte clonal selection, peripheral tolerance
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cancer Biomarkers, Cell Biology, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Agata Y, et al. 1996. Int. Immunol. 8:765.
3. Nishimura H, et al. 2001. Science 291:319.
4. Ishida Y, et al. 1992. EMBO J. 11:3887.

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
RMP1-30 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed Death-1, CD279, PDCD1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RMP1-30
Con A (3-day) activated C57BL/6 mouse splenocytes stained with RMP1-30 PE
  • RMP1-30
    Con A (3-day) activated C57BL/6 mouse splenocytes stained with RMP1-30 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
109103 50 µg DKK725
Check Availability


Need larger quantities of this item?
Request Bulk Quote
109104 200 µg DKK2097
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279 is a 50-55 kD immunoglobulin superfamily member also known as programmed death-1 (PD-1). PD-1 is expressed on a subset of CD4-CD8- thymocytes and on activated T and B cells. PD-1 is thought to be involved in lymphocyte clonal selection and peripheral tolerance. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse PD-1 transfected BHK cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RMP1-30 antibody does not block the binding of PD-1 to B7-H1 and B7-DC1.

Application References
  1. Matsumoto K, et al. 2004. J. Immunol. 172:2530.
  2. Raimondi G, et al. 2006. J. Immunol. 176:2808. (FC) PubMed
  3. King IL, et al. 2009. J. Exp Med 206:1001. (FC) PubMed
Product Citations
  1. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  2. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  3. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  4. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  5. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  8. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  9. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  10. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  11. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  12. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  13. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  14. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  15. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  16. Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
  17. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  18. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  19. Bally A, et al. 2015. J Immunol. 194:4545. PubMed
  20. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  21. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  22. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  23. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  24. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  25. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  26. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  27. An J, et al. 2022. iScience. 25:103570. PubMed
  28. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  29. Zeng W, et al. 2016. Sci Rep. 6:36560. PubMed
  30. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  31. Karnowski A, et al. 2012. J Exp Med. 209:2049. PubMed
  32. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  33. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  34. Park S, et al. 2014. J Leukoc Biol. 95:621. PubMed
  35. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  36. Li H, et al. 2020. Nature. 584:274. PubMed
  37. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  38. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  39. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  40. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  41. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  42. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  43. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  44. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  45. Puleston D, et al. 2014. Elife. 3:3706. PubMed
  46. Park H, et al. 2012. Cell Immunol. 278:76. PubMed
  47. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  48. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  49. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  50. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  51. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  52. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  53. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  54. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  55. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  56. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  57. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  58. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  59. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  60. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  61. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  62. Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
  63. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  64. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  65. Bally A, et al. 2015. J Immunol. 194:4545. PubMed
  66. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  67. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  68. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  69. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  70. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  71. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  72. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  73. An J, et al. 2022. iScience. 25:103570. PubMed
  74. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  75. Zeng W, et al. 2016. Sci Rep. 6:36560. PubMed
  76. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  77. Karnowski A, et al. 2012. J Exp Med. 209:2049. PubMed
  78. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  79. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  80. Park S, et al. 2014. J Leukoc Biol. 95:621. PubMed
  81. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  82. Li H, et al. 2020. Nature. 584:274. PubMed
  83. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  84. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  85. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  86. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  87. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  88. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  89. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  90. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  91. Puleston D, et al. 2014. Elife. 3:3706. PubMed
  92. Park H, et al. 2012. Cell Immunol. 278:76. PubMed
RRID
AB_313420 (BioLegend Cat. No. 109103)
AB_313421 (BioLegend Cat. No. 109104)

Antigen Details

Structure
Ig superfamily, 50-55 kD
Distribution

Subset of double negative thymocytes, activated T and B cells

Function
Lymphocyte clonal selection, peripheral tolerance
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cancer Biomarkers, Cell Biology, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Agata Y, et al. 1996. Int. Immunol. 8:765.
3. Nishimura H, et al. 2001. Science 291:319.
4. Ishida Y, et al. 1992. EMBO J. 11:3887.

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account